Goldman Sachs analyst Richard Law lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $15 from $29 and keeps a Neutral rating ...

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and ...

Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

In the United States, ONS-5010 / LYTENAVA™ (bevacizumab-vikg) is investigational.

Precigen's PRGN-2012 and UltraCAR-Ts offer groundbreaking therapies. Read why PGEN stock is a strong pick, with major ...

Operator: Please standby. Welcome, ladies and gentlemen, to the Fourth Quarter and Fiscal Year 2024 Earnings Conference Call ...

Organogenesis ( ORGO -5.54%) Q4 2024 Earnings Call Feb 27, 2025, 5:00 p.m. ET ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

The firm's biologics license application for TLX250-CDx was granted priority review and a decision is expected in August.

In the third quarter of 2025, the Company expects to present data from its ongoing Phase I/II studies of AMT-130 in support of a potential BLA submission. The update will include follow-up data on all ...